For example, investigating the effects of inhibiting IL-18 activity with humanized monoclonal antibodies to IL-18 (82), or suppression of NLRP3-inflammasome activation, is supported by preliminary data from uncontrolled, but more than one, clinical studies in patients with COVID-19 reporting a beneficial effect of inhibiting NLRP3-inflammasome activity with colchicine (83, 84). The gene discussed is NLRP3; the disease is COVID-19.